ClinicalTrials.gg
TerminatedNCT05568225Updated Sep 3, 2026Results posted

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

A Phase 2 interventional study of Etavopivat in Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R, sponsored by Forma Therapeutics, Inc.. Terminated at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Forma Therapeutics, Inc. (part of Novo Nordisk A/S) · Phase 2, Interventional, and Treatment

Why this study was terminated
Futility assessment concluded low likelihood of the trial showing meaningful patient benefit.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.

Enrollment
306th of 395
17 · median 72
Started
2022
with 12 others
Phase 2
109 of 464
9 open now
Registered
415th of 464
by date

Among the 464 studies in Anemia with a site in United States, this one is the 306th largest by enrollment of the 395 interventional ones that give a count, is one of 13 that started in 2022, is one of 109 in phase 2, and was the 415th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 464 studies in Anemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.

03

Conditions studied

  • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

Keywords

  • Anemia
  • Myelodysplastic Syndromes
  • MDS
  • Pyruvate Kinase
  • Activator
  • Transfusion dependent
  • FT-4202
  • Etavopivat
  • IPSS-R very low risk
  • IPSS-R low risk
  • IPSS-R intermediate risk
  • ESA refractory
  • ESA intolerant
  • Luspatercept refractory
  • Luspatercept intolerant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has provided documented ; the informed consent form (ICF) must be reviewed and signed by each patient prior to any study-related assessments/procedures being conducted.
  2. Age ≥ 18 years at time of first dose.
  3. Patients, if female and of , must agree to use acceptable methods of and agree not to donate ova from study start to 90 days after the last dose of study drug, and who if male are willing to use acceptable methods of contraception and agree not to donate sperm, from study start to 90 days after the last dose of study drug.
  4. Documented diagnosis of idiopathic/de novo MDS according to World Health Organization (WHO) classification that meets the IPSS-R classification of very low, low, or intermediate risk disease, and:

    • \< 5% blasts in bone marrow based on local pathology review
    • \< Intermediate risk cytogenetic abnormalities per IPSS-R
  5. Anemia defined as:

    • Non-transfusion dependent (NTD): Subjects with mean concentration \< 10.0 g/dL of 2 measurements (1 performed within 3 days prior to Day 1 and the other performed 7 to 28 days prior to Day 1, not influenced by RBC transfusion within 7 days of measurement) and \< 3 RBC transfusions for anemia in the prior 16 weeks before Day 1 of etavopivat dosing

    OR

    • Transfusion dependent (TD): Subjects having received ≥ 3 units of RBCs for the treatment of anemia within 16 weeks prior to Day 1
  6. Serum erythropoietin level > 200 U/L, OR, if ≤ 200 U/L, subject is non-responsive, , or intolerant to erythropoiesis-stimulating agents, or erythropoiesis-stimulating agents are or unavailable.
  7. performance status of ≤ 2
  8. Subject is non-responsive, refractory, or intolerant to luspatercept, or luspatercept is contraindicated or not indicated.
  9. No alternative treatment options are available and/or appropriate for the subject, at the discretion of the investigator.
  10. Patient is willing and able to adhere to the study visit schedule and other protocol requirements

Exclusion criteria

EXCLUSION CRITERIA:

[MDS History]

  1. MDS associated with del 5q cytogenetic abnormality and known TP53 abnormality
  2. Therapy-associated MDS (eg. t-MDS) that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases
  3. Known history of acute myeloid leukemia (AML)

    [Medical Conditions]

  4. Female who is breast feeding or pregnant
  5. Known anemia due to iron, vitamin B12, or folate deficiencies, or or hereditary hemolytic anemia, or gastrointestinal bleeding
  6. \< 500/µL (0.5 x 10\^9/L)
  7. count \< 50,000/µL (50 x 10\^9/L) without transfusion support within 2 weeks
  8. Hepatic dysfunction characterized by:

    • (ALT) > 5.0 × (ULN)
    • Total > 3.0 × ULN
    • History of cirrhosis
  9. Severe renal dysfunction (estimated at the Screening visit; calculated by the local laboratory \< 30 mL/min/1.73 m\^2 ) or on chronic dialysis.
  10. Patients with clinically significant and active bacterial, fungal, parasitic, or viral infection.

    • Patients with acute bacterial, fungal, parasitic, or viral infection requiring systemic therapy should delay Screening/ enrollment until active therapy has been completed.
    • Patients with acute viral infections without available therapies (eg, coronavirus disease 2019 [COVID-19]) should delay Screening/ enrollment until the acute infection has resolved.

    Note: Infection prophylaxis is allowed.

  11. Known (HIV) positivity
  12. Active infection with virus (hepatitis B surface antigen [HepBsAg] and hepatitis B core antibody [HepBcAb] positive)
  13. Active infection
  14. History of , other than MDS, within the past 2 years prior to treatment Day 1 requiring systemic chemotherapy and/or radiation.

    • Patients with malignancy considered surgically cured are eligible (eg, non-melanoma skin cancer, carcinoma in situ of the cervix, or carcinoma in situ of the breast)
    • Patients with incidental histologic findings of prostate cancer (T1a or T1b) are eligible
  15. History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:

    • Unstable angina pectoris or myocardial infarction or elective coronary intervention
    • Heart disease, heart failure as classified by the classification 3 or higher, or significant arrhythmia requiring treatment,
    • Pulmonary fibrosis or pulmonary hypertension which are clinically significant ie, ≥ Grade 3 National Cancer Institute (NCI) (CTCAE) version 4.0 (or higher)
  16. Uncontrolled hypertension, defined as repeated elevation of diastolic blood pressure ≥ 100 mmHg despite adequate treatment
  17. Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable).

    [Prior/Concomitant Therapy]

  18. Prior treatment with azacitidine (injectable or oral) or decitabine
  19. Use of erythropoietin, other hematopoietic growth factor treatment or lenalidomide within 30 days of starting study treatment or anticipated need for such agents during the study.
  20. Prior use of luspatercept:

    • NTD patients must not have received luspatercept within 30 days prior to Day 1 treatment
    • TD patients must not have received luspatercept within 16 weeks prior to Day 1 treatment
  21. Receiving or use of concomitant medications that are strong inducers of cytochrome P450 (CYP)3A4/5 (see Appendix F) within 2 weeks of starting study treatment or anticipated need for such agents during the study.
  22. Prior or autologous stem cell transplant
  23. Initiation of a new chelation therapy within 3 months before the first dose of study treatment.

    [Prior/Concurrent Clinical Study Experience]

  24. Participated in another clinical trial of an agent (or medical device) within 30 days or 5 half-lives of date of , whichever is longer, or is currently participating in another trial of an investigational agent (or medical device).

    [Other Exclusions]

  25. Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Etavopivat 400 mg QD daily

    Non-transfusion dependent (NTD), Low transfusion burden (LTB) , and High transfusion burden (HTB) patients

    Drug: Etavopivat

Interventions

  • 400 mg once daily

    Also known as: FT-4202

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for >=8 Weeks Within 24 Weeks of Etavopivat Treatment

    This outcome measure reported on the combined incidence of NTD, LTB and HTB in terms of (HI-E) response for \>=8 weeks duration in participants with myelodysplastic syndromes (MDS) within 24 weeks. The participants were allocated to the following arms which were defined as: 1) NTD: \>=1.5 grams per deciliter (g/dL) increase in haemoglobin (Hb) from baseline maintained \>=8 consecutive weeks and no transfusion of RBC units for anemia over a continuous 8-week treatment period; 2) LTB: absence of any transfusion for \>=8 consecutive weeks; and 3) HTB: reduction by \>=50 percent (%) of RBC units for \>=8 consecutive weeks.

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Percentage of Participants With Hematologic Improvement-Erythroid (HI-E) Response for =>8 Weeks Within 16 and 48 Weeks of Etavopivat

    This outcome measure focused on the combined incidence of NTD, LTB and HTB participants, evaluating HI-E lasting =\>8 weeks in individuals with MDS within 16 weeks and 48 weeks. Participant's response were defined as follows: 1) NTD: an increase of =\>1.5 g/dL in Hb maintained for =\>8 consecutive weeks without any RBC transfusions for anemia; 2) LTB: no transfusions over =\>8 consecutive weeks; and 3) HTB: a reduction of =\>50% in RBC units for =\>8 consecutive weeks.

    Time frame: 48 weeks

  2. Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for =>16 Weeks Within 24 and 48 Weeks of Etavopivat

    This outcome measure focused on the combined incidence of NDT, LTB and HTB participants, evaluating HI-E response lasting =\>16 weeks in individuals with MDS within 24 weeks and 48 weeks. Participant's response were defined as follows: 1) NTD: an increase of =\>1.5 g/dL in Hb maintained for =\>16 consecutive weeks without any RBC transfusions for anemia; 2) LTB: no transfusions over =\>16 consecutive weeks; and 3) HTB: a reduction of =\>50% in RBC units for =\>16 consecutive weeks.

    Time frame: 48 weeks

  3. Number of All Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Related to Etavopivat

    This outcome measures the total number of AEs and SAEs in participants, including AEs related to etavopivat. AEs are any unfavorable medical occurrences in participants taking the medicinal product, regardless of causality. They include new or worsening symptoms, abnormal lab findings, and exacerbations of existing conditions, documented from the first dose through 28 days after the last dose. SAEs are severe AEs that result in death, are life-threatening, require hospitalization, lead to significant disability, or involve congenital anomalies. Important medical events posing risks to the participants are also classified as SAEs. Treatment Emergent Adverse Events (TEAEs) are AEs occurring after treatment initiation, aiding in the safety assessment of etavopivat. TEAEs will be considered drug-related if assessed by the Investigator as possibly related or related, or if relationship is missing.

    Time frame: From baseline up to 48 weeks

  4. Number of Premature Discontinuations, Dose Interruptions, and Dose Reductions

    The outcome measures the total number of premature discontinuations, dose interruptions and dose reductions. Premature discontinuation was defined as any discontinuation prior to week 48. A dose interruption is a temporary halt in treatment due to an AE, while a dose reduction involves lowering the dosage of the drug when AEs occur. If a participant tolerates a reduced dose for 14 days, a rechallenge with the original dose may occur after a clinic visit, but any new Grade 3 or higher AEs require treatment discontinuation and consultation with the Global Medical Monitor before resuming.

    Time frame: Within 48 weeks

  5. Overall Response Rate

    The Overall Response Rate (ORR) is defined as the percentage of participants who achieve a predefined level of response according to the 2006 International Working Group (IWG) criteria, assessed at each scheduled evaluation.

    Time frame: Up to 48 weeks

  6. Duration of Response

    This outcome measure reported duration of response which was defined as duration of response will be summarized with quantiles based on product limit estimates (ie, Kaplan-Meier). Duration of response is defined as the time from date of first known incidence of a 2006 IWG criteria response to the most recent date that the 2006 IWG (International Working Group) criteria is not met following the initial response. If the participant has met IWG criteria throughout the period following the initial response, the participant will be censored at the latest date of end of study, loss to follow-up, or death.

    Time frame: Up to 48 weeks

  7. Reduction in RBC Transfusions for >=8 Weeks in Participants With LTB or HTB at Study Entry

    This outcome measure reports reduction in RBC transfusion by 8-week interval in participants with LTB and HTB.

    Time frame: Up to 48 weeks

  8. Percent Change From Baseline in RBC Transfusion Independence for =>8 Weeks in Participants With LTB or HTB at Study Entry

    This outcome measure is percent change in RBC transfusion by 8-week interval in participants with LTB and HTB. Percent reduction from baseline in RBC transfusion burden is defined as -100×(Total RBC Units Transfused During Interval)/(Baseline RBC Units Transfused Per 8 Weeks).

    Time frame: Up to 48 weeks

  9. Change From Baseline in Neutrophils and/or Platelets Counts

    This outcome measure reports the change from baseline in neutrophils and/or platelets counts from baseline to week 48

    Time frame: Baseline (week 0), week 48

  10. Decrease in Ferritin and Transferrin Saturation (TSAT)

    This outcome measure were to report decrease in ferritin and TSAT from baseline to Week 48.

    Time frame: Up to 48 weeks

  11. Decrease in Iron Chelation Therapy

    This outcome measure were to report decrease of Iron chelation therapy and will be recorded at Screening and on an ongoing basis throughout the study.

    Time frame: up to 48 weeks

  12. Overall Survival

    Overall survival is defined as the time from first dose to date of death. If the participant was alive at last contact, the end date will be censored at the latest of either end of study, loss to follow-up, or study discontinuation.

    Time frame: Within 48 weeks

  13. Etavopivat Plasma Concentrations

    This outcome measure reported Etavopivat plasma concentrations in order to assess the PK properties of etavopivat in participants with MDS. PK parameters included but not limited to were: Time to maximum observed plasma concentration, area under the plasma concentration-time curve from time zero until the last quantifiable time point (AUC0-last), from time zero to infinity (AUC0-inf), for a dosing interval (AUCtau/AUC0-24).) However due to early termination of the study, the PK parameters were not assessed and only the plasma concentrations could be assessed.

    Time frame: Weeks 1 and 4 pre-dose, post-dose 1, 2, 4, 6 hours.Week 2 and EOT (week 48):pre-dose, post-dose 1, 2 hours

  14. RBC 2,3-diphosphoglycerate (2,3-DPG) and Adenosine Triphosphate (ATP) Levels Over Time

    Etavopivat plasma concentrations were collected in order to assess the pharmacodynamic (PD) properties of etavopivat in participants with MDS.

    Time frame: Within 48 weeks

07

Results

Posted Oct 22, 2025
Limitations and caveats
The futility assessment concluded low likelihood of the trial showing meaningful participant benefit. The decision was based on a predefined QTL that required 5 or more participants to complete 16 weeks of treatment or not having 8 or more consecutive weeks of primary endpoint data. However 7 participants did not fulfill this requirement, leading to the early termination of the study.

Participant flow

The trial was conducted at 10 sites in 4 countries.

Primary Treatment Period
Participant flow — Primary Treatment Period
MilestoneNon-transfusion DependentLow Transfusion BurdenHigh Transfusion Burden
Started359
Efficacy evaluable set (ees)124
Safety population359
Full analysis set (fas)359
Pharmacokinetic (pk) set359
Completed124
Not completed235
Withdrew: Termination of the study by the sponsor001
Withdrew: Physician decision010
Withdrew: Disease progression010
Withdrew: Lack of efficacy010
Withdrew: Withdrawal of conset104
Withdrew: Adverse event100
Extension Treatment Period
Participant flow — Extension Treatment Period
MilestoneNon-transfusion DependentLow Transfusion BurdenHigh Transfusion Burden
Started124
Completed121
Not completed003
Withdrew: Termination of the study by the sponsor001
Withdrew: Protocol violation001
Withdrew: Lack of efficacy001

Outcome measures

PrimaryPercentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for >=8 Weeks Within 24 Weeks of Etavopivat Treatment

This outcome measure reported on the combined incidence of NTD, LTB and HTB in terms of (HI-E) response for \>=8 weeks duration in participants with myelodysplastic syndromes (MDS) within 24 weeks. The participants were allocated to the following arms which were defined as: 1) NTD: \>=1.5 grams per deciliter (g/dL) increase in haemoglobin (Hb) from baseline maintained \>=8 consecutive weeks and no transfusion of RBC units for anemia over a continuous 8-week treatment period; 2) LTB: absence of any transfusion for \>=8 consecutive weeks; and 3) HTB: reduction by \>=50 percent (%) of RBC units for \>=8 consecutive weeks.

Time frame:
From Baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for >=8 Weeks Within 24 Weeks of Etavopivat Treatment
Percentage of participantsNon-transfusion DependentLow Transfusion BurdenHigh Transfusion Burden
Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for >=8 Weeks Within 24 Weeks of Etavopivat Treatment05025
SecondaryPercentage of Participants With Hematologic Improvement-Erythroid (HI-E) Response for =>8 Weeks Within 16 and 48 Weeks of Etavopivat

This outcome measure focused on the combined incidence of NTD, LTB and HTB participants, evaluating HI-E lasting =\>8 weeks in individuals with MDS within 16 weeks and 48 weeks. Participant's response were defined as follows: 1) NTD: an increase of =\>1.5 g/dL in Hb maintained for =\>8 consecutive weeks without any RBC transfusions for anemia; 2) LTB: no transfusions over =\>8 consecutive weeks; and 3) HTB: a reduction of =\>50% in RBC units for =\>8 consecutive weeks.

Time frame:
48 weeks

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for =>16 Weeks Within 24 and 48 Weeks of Etavopivat

This outcome measure focused on the combined incidence of NDT, LTB and HTB participants, evaluating HI-E response lasting =\>16 weeks in individuals with MDS within 24 weeks and 48 weeks. Participant's response were defined as follows: 1) NTD: an increase of =\>1.5 g/dL in Hb maintained for =\>16 consecutive weeks without any RBC transfusions for anemia; 2) LTB: no transfusions over =\>16 consecutive weeks; and 3) HTB: a reduction of =\>50% in RBC units for =\>16 consecutive weeks.

Time frame:
48 weeks

No measurements were reported for this outcome.

SecondaryNumber of All Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Related to Etavopivat

This outcome measures the total number of AEs and SAEs in participants, including AEs related to etavopivat. AEs are any unfavorable medical occurrences in participants taking the medicinal product, regardless of causality. They include new or worsening symptoms, abnormal lab findings, and exacerbations of existing conditions, documented from the first dose through 28 days after the last dose. SAEs are severe AEs that result in death, are life-threatening, require hospitalization, lead to significant disability, or involve congenital anomalies. Important medical events posing risks to the participants are also classified as SAEs. Treatment Emergent Adverse Events (TEAEs) are AEs occurring after treatment initiation, aiding in the safety assessment of etavopivat. TEAEs will be considered drug-related if assessed by the Investigator as possibly related or related, or if relationship is missing.

Time frame:
From baseline up to 48 weeks
Reported as:
Number · Events
Number of All Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Related to Etavopivat
EventsNon-transfusion DependentLow Transfusion BurdenHigh Transfusion Burden
AE333354
SAE106
AEs related to etavopivat001
AEs possibly related etavopivat836
SecondaryNumber of Premature Discontinuations, Dose Interruptions, and Dose Reductions

The outcome measures the total number of premature discontinuations, dose interruptions and dose reductions. Premature discontinuation was defined as any discontinuation prior to week 48. A dose interruption is a temporary halt in treatment due to an AE, while a dose reduction involves lowering the dosage of the drug when AEs occur. If a participant tolerates a reduced dose for 14 days, a rechallenge with the original dose may occur after a clinic visit, but any new Grade 3 or higher AEs require treatment discontinuation and consultation with the Global Medical Monitor before resuming.

Time frame:
Within 48 weeks
Reported as:
Number · Events
Number of Premature Discontinuations, Dose Interruptions, and Dose Reductions
EventsNon-transfusion DependentLow Transfusion BurdenHigh Transfusion Burden
Premature discontinuations100
Dose interruptions002
Dose reductions000
SecondaryOverall Response Rate

The Overall Response Rate (ORR) is defined as the percentage of participants who achieve a predefined level of response according to the 2006 International Working Group (IWG) criteria, assessed at each scheduled evaluation.

Time frame:
Up to 48 weeks

No measurements were reported for this outcome.

SecondaryDuration of Response

This outcome measure reported duration of response which was defined as duration of response will be summarized with quantiles based on product limit estimates (ie, Kaplan-Meier). Duration of response is defined as the time from date of first known incidence of a 2006 IWG criteria response to the most recent date that the 2006 IWG (International Working Group) criteria is not met following the initial response. If the participant has met IWG criteria throughout the period following the initial response, the participant will be censored at the latest date of end of study, loss to follow-up, or death.

Time frame:
Up to 48 weeks

No measurements were reported for this outcome.

SecondaryReduction in RBC Transfusions for >=8 Weeks in Participants With LTB or HTB at Study Entry

This outcome measure reports reduction in RBC transfusion by 8-week interval in participants with LTB and HTB.

Time frame:
Up to 48 weeks
Reported as:
Mean · Total RBS units
Reduction in RBC Transfusions for >=8 Weeks in Participants With LTB or HTB at Study Entry
Total RBS unitsLow Transfusion BurdenHigh Transfusion Burden
Week 1-83.0 ± 2.835.8 ± 2.63
Week 9-162.5 ± 2.126.3 ± 1.71
Week 17-243.5 ± 2.127.5 ± 3.00
Week 25-325.5 ± 0.717.3 ± 1.15
Week 33-405.0 ± 4.246.7 ± 1.15
Week 41-484.5 ± 2.127.5 ± 2.12
SecondaryPercent Change From Baseline in RBC Transfusion Independence for =>8 Weeks in Participants With LTB or HTB at Study Entry

This outcome measure is percent change in RBC transfusion by 8-week interval in participants with LTB and HTB. Percent reduction from baseline in RBC transfusion burden is defined as -100×(Total RBC Units Transfused During Interval)/(Baseline RBC Units Transfused Per 8 Weeks).

Time frame:
Up to 48 weeks
Reported as:
Mean · Percent change of total RBC units
Percent Change From Baseline in RBC Transfusion Independence for =>8 Weeks in Participants With LTB or HTB at Study Entry
Percent change of total RBC unitsLow Transfusion BurdenHigh Transfusion Burden
Week 1-8-20.83 ± 64.81868.75 ± 156.994
Week 9-16-33.33 ± 47.14068.75 ± 98.219
Week 17-24-4.17 ± 41.248120.83 ± 191.183
Week 25-3258.33 ± 11.785127.78 ± 149.381
Week 33-4033.33 ± 94.28194.44 ± 91.793
Week 41-4825.00 ± 35.35550.00 ± 0
SecondaryChange From Baseline in Neutrophils and/or Platelets Counts

This outcome measure reports the change from baseline in neutrophils and/or platelets counts from baseline to week 48

Time frame:
Baseline (week 0), week 48
Reported as:
Mean · 10^9 cells per liter
Change From Baseline in Neutrophils and/or Platelets Counts
10^9 cells per literNon-transfusion DependentLow Transfusion BurdenHigh Transfusion Burden
Neutrophils-3.200 ± NA-0.950 ± 0.0707-0.100 ± NA
Platelets counts43.0 ± NA-51.0 ± 205.06-8.0 ± NA
SecondaryDecrease in Ferritin and Transferrin Saturation (TSAT)

This outcome measure were to report decrease in ferritin and TSAT from baseline to Week 48.

Time frame:
Up to 48 weeks

No measurements were reported for this outcome.

SecondaryDecrease in Iron Chelation Therapy

This outcome measure were to report decrease of Iron chelation therapy and will be recorded at Screening and on an ongoing basis throughout the study.

Time frame:
up to 48 weeks

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival is defined as the time from first dose to date of death. If the participant was alive at last contact, the end date will be censored at the latest of either end of study, loss to follow-up, or study discontinuation.

Time frame:
Within 48 weeks

No measurements were reported for this outcome.

SecondaryEtavopivat Plasma Concentrations

This outcome measure reported Etavopivat plasma concentrations in order to assess the PK properties of etavopivat in participants with MDS. PK parameters included but not limited to were: Time to maximum observed plasma concentration, area under the plasma concentration-time curve from time zero until the last quantifiable time point (AUC0-last), from time zero to infinity (AUC0-inf), for a dosing interval (AUCtau/AUC0-24).) However due to early termination of the study, the PK parameters were not assessed and only the plasma concentrations could be assessed.

Time frame:
Weeks 1 and 4 pre-dose, post-dose 1, 2, 4, 6 hours.Week 2 and EOT (week 48):pre-dose, post-dose 1, 2 hours
Reported as:
Mean · ng/mL
Etavopivat Plasma Concentrations
ng/mLNon-transfusion DependentLow Transfusion BurdenHigh Transfusion Burden
Week 1 predose0 ± 00 ± 00 ± 0
Week 1 post-dose 1 hour379.77 ± 292.748904.80 ± 521.0001016.78 ± 794.503
Week 1 post-dose 2 hour751.67 ± 393.465579.60 ± 403.593519.11 ± 273.776
Week 1 post-dose 4 hour274.50 ± 86.974203.80 ± 134.884165.16 ± 64.895
Week 1 post-dose 6 hour63.50 ± NA101.02 ± 67.69383.74 ± 40.170
Week 2 pre-dose27.20 ± 17.84319.08 ± 9.03719.20 ± 12.240
Week 2 post-dose 1 hour1156.00 ± 371.198899.40 ± 442.5551076.44 ± 693.907
Week 2 post-dose 2 hour927.00 ± 310.1401024.00 ± 530.102661.78 ± 392.238
Week 4 predose17.04 ± 11.54024.34 ± 23.33320.26 ± 9.289
Week 4 post-dose 1 hour1050.00 ± 28.284386.90 ± 214.249913.20 ± 1013.207
Week 4 post-dose 2 hour526.00 ± 134.350453.40 ± 179.140678.49 ± 379.918
Week 4 post-dose 4 hour151.50 ± 12.021383.73 ± 261.103297.90 ± 282.646
Week 4 post-dose 6 hour60.75 ± 11.526148.13 ± 113.650121.34 ± 115.306
End of treatment pre-dose—21.60 ± 5.79824.20 ± NA
End of treatment post-dose 1 hours—1620.00 ± NA1680.00 ± NA
End of treatment post-dose 2 hours—571.00 ± NA815.00 ± NA
SecondaryRBC 2,3-diphosphoglycerate (2,3-DPG) and Adenosine Triphosphate (ATP) Levels Over Time

Etavopivat plasma concentrations were collected in order to assess the pharmacodynamic (PD) properties of etavopivat in participants with MDS.

Time frame:
Within 48 weeks

No measurements were reported for this outcome.

Adverse events

Collected over Up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-transfusion Dependent0/3 (0%)1/3 (33.3%)3/3 (100%)
Low Transfusion Burden0/5 (0%)0/5 (0%)5/5 (100%)
High Transfusion Burden0/9 (0%)3/9 (33.3%)8/9 (88.9%)
Most frequent serious events
Most frequent serious events
EventNon-transfusion DependentLow Transfusion BurdenHigh Transfusion Burden
Cardiac failureCardiac disorders1/30/50/9
Angina pectorisCardiac disorders0/30/51/9
Arterial ruptureVascular disorders0/30/51/9
Hip fractureInjury, poisoning and procedural complications0/30/51/9
Peripheral arterial occlusive diseaseVascular disorders0/30/51/9
Post procedural haemorrhageInjury, poisoning and procedural complications0/30/51/9
Staphylococcal infectionInfections and infestations0/30/51/9
Most frequent other events
Showing 10 of 64
Most frequent other events
EventNon-transfusion DependentLow Transfusion BurdenHigh Transfusion Burden
AnxietyPsychiatric disorders2/31/50/9
DyspnoeaRespiratory, thoracic and mediastinal disorders2/30/51/9
Lymphocyte count decreasedInvestigations2/30/50/9
ThrombocytopeniaBlood and lymphatic system disorders2/30/50/9
PneumoniaInfections and infestations0/32/50/9
AnaemiaBlood and lymphatic system disorders1/30/50/9
Atrioventricular block second degreeCardiac disorders1/30/50/9
Cardiac failureCardiac disorders1/31/50/9
CoughRespiratory, thoracic and mediastinal disorders1/30/51/9
FatigueGeneral disorders1/30/51/9

Baseline characteristics

FAS included all participants who signed the informed consent and received at least 1 dose of etavopivat.

Age, Continuous
Age, Continuous(Years)Non-transfusion DependentLow Transfusion BurdenHigh Transfusion BurdenTotal
Mean77.3 ± 5.6980.2 ± 3.4971.2 ± 8.1174.9 ± 7.58
Sex: Female, Male
Sex: Female, Male(Participants)Non-transfusion DependentLow Transfusion BurdenHigh Transfusion BurdenTotal
Female0134
Male34613
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Non-transfusion DependentLow Transfusion BurdenHigh Transfusion BurdenTotal
Race: White34714
Race: Not reported0123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Non-transfusion DependentLow Transfusion BurdenHigh Transfusion BurdenTotal
Ethnicity: Not Hispanic or Latino34613
Ethnicity: Hispanic or Latino0112
Ethnicity: Not Reported0022
08

Study locations

10 sites
  • University of Miami Hospital and Clinics
    Miami, Florida 33136, United States
  • Ocala Oncology
    Ocala, Florida 34474, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • University of British Columbia - St. Paul's Hospital
    Vancouver, British Columbia V6Z 2K5, Canada
  • Nice University Hospital - Hôpital de l'Archet
    Route de Saint-Antoine, Nice 06200, France
  • Hopital Saint Louis
    Paris, France
  • Universitoetsklinikum Heidelberg
    Heidelberg, Germany
  • Universitaetsklinikum Muenster
    Münster, Germany
  • Universitoetsklinikum Halle (Saale)
    Münster, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Jul 2024, 20 months.

Results were first posted in Oct 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2022
First posted
Oct 5, 2022
StartActual
Nov 15, 2022
Primary completionActual
Jul 15, 2024
CompletionActual
Jul 15, 2024
Results first posted
Oct 22, 2025
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05568225
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Nov 15, 2022
Primary completion
Jul 15, 2024
Completion
Jul 15, 2024
Results posted
Oct 22, 2025
Last update
Sep 3, 2026

Study contacts

Clinical Transparency (dept. 2834), MD
study director · Novo Nordisk A/S

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etavopivat

Start the discussion